Accessibility Menu
Nuvation Bio logo

Nuvation Bio(NYSE) NUVB

Market Cap$2.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-27%
5 Year-28%
1 Year+134%
1 Month+5%
Premium Feature
Moneyball Superscore
64/100
$6.95
-2.18%
-0.15Today
After hours$6.94-$0.01 (-0.14%)
Nuvation Bio last closing stock price
MetricPriceDate
Last closeUSD 6.962026-08-26
Nuvation Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.13%USD 7.262026-08-19
1 month+4.5%USD 6.662026-07-27
3 month+46.53%USD 4.752026-05-28
Year to date-22.32%USD 8.962025-12-31
1 year+133.56%USD 2.982025-08-26
3 year+324.39%USD 1.642023-08-25
5 year-27.88%USD 9.652021-08-27
Since inception-26.8%USD 9.702020-08-26

Nuvation Bio Financials at a Glance

Market Cap

$2.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$169.90M

Net Income (TTM)

-$149.83M

EPS (TTM)

-$0.44

P/E Ratio

-16.00

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Price

$6.95

Volume

58

Open

$7.09

Previous Close

$6.96

Daily Range

$6.91 - $7.12

52-Week Range

$2.87 - $9.75

Estimated Earnings Date

Nov 2, 2026

NUVB News

SellAlert-Red.png

Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?

Jonathan PoncianoJun 29, 2026
Insider.png

Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum

Brendan CoffeyJun 17, 2026
SellAlert-Purple.png

Insider Sells 200K Shares of Biotech Company Nuvation Bio

Pamela KockApr 13, 2026
BuyAlert-Purple.png

Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy

Jonathan PoncianoMar 3, 2026
GettyImages-1477214805.jpg

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

Jonathan PoncianoNov 3, 2025
Scientists in a lab, monitor, microscope

Why Nuvation Bio Stock Is Skyrocketing Today

Keith SpeightsSep 30, 2025
Foolcom-Featured.png

NUVB Sales Jump 1,043% on Drug Launch

Motley Fool Markets TeamAug 7, 2025

NUVB: Motley Fool Moneyball Superscore

64

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nuvation Bio

Nuvation Bio Inc. makes medicines to treat difficult forms of cancer. Its products help patients by targeting tumors with high precision. These therapies help people fight specific types of lung cancer.

Fighting Cancer with Small Molecules

  • IBTROZI: Orally administered medicine approved for adults with a specific lung cancer mutation.
  • Safusidenib: Investigational drug designed to block mutant proteins that drive brain tumor growth.
  • BET Inhibitors: Experimental compounds like NUV-868 that target proteins involved in cell growth.
  • Drug-Drug Conjugates: Technology platform used to deliver cancer-killing agents directly to tumor cells.

Growing the International Reach

  • Launched IBTROZI in the U.S. in June 2025 for patients with lung cancer.
  • Partnered with Eisai in January 2026 to commercialize therapies in Europe and other territories.
  • Amended a license agreement with Daiichi Sankyo in April 2026 to include rights in Japan.
  • Submitted marketing applications for taletrectinib in Europe and the United Kingdom during early 2026.

What Sets the Science Apart

The company identifies validated cancer targets and uses medicinal chemistry to improve existing therapies. Leadership includes the founder of Medivation, who previously developed major oncology treatments like Xtandi.

Key Financial Figures

  • Total revenue reached $31.7 million for the three months ended June 30, 2026.
  • Product revenue from IBTROZI sales totaled $23.2 million during the second quarter of 2026.
  • Collaboration and license revenue increased by $66.5 million for the six months ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities reached $661 million as of June 30, 2026.
  • Completed a registered public offering of convertible senior notes for $287.5 million in July 2026.

Bottom Line

Nuvation Bio has transitioned from a research firm to a commercial stage enterprise with an approved lung cancer drug. Its focus on improving established cancer targets drives its global partnership strategy and drug pipeline.

AI Generated • Aug 6, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

298

CEO

David T. Hung, MD

Website

www.nuvationbio.com

Headquarters

New York City, NY 10036, US

NUVB Financials

Key Financial Metrics (TTM)

Gross Margin

93.94%

Operating Margin

-81.00%

Net Income Margin

-88.19%

Return on Equity

-49.73%

Return on Capital

-67.45%

Return on Assets

-20.12%

Earnings Yield

-6.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

352.12M

Volume

58

Avg. Volume

6.72M

Financials (TTM)

Gross Profit

$159.60M

Operating Income

-$137.63M

EBITDA

-$127.04M

Operating Cash Flow

-$82.62M

Capital Expenditure

-$101.00K

Free Cash Flow

-$82.72M

Cash & ST Invst.

$660.96M

Total Debt

$252.14M

Nuvation Bio Performance Analysis

Nuvation Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 7,873,000N/A
20252025-12-31USD 62,902,000699.0%
Nuvation Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30171.5%
Q42025-12-31219.1%
Q12026-03-3198.8%
Q22026-06-30-61.9%
Nuvation Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.489.5%
20232023-12-31USD -0.35-28.0%
20242024-12-31USD -2.11510.2%
20252025-12-31USD -0.60-71.6%
Nuvation Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.9%
Q42025-12-3131.3%
Q12026-03-31113.0%
Q22026-06-30-1358.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$31.69M

+555.6%

Gross Profit

$30.78M

+1263.6%

Gross Margin

97.13%

N/A

Market Cap

$2.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.04M

N/A

Employees

305

N/A

Net Income

-$62.84M

-6.5%

EBITDA

-$55.55M

+4.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$660.96M

+8.8%

Total Debt

$252.14M

+336.5%

Accounts Receivable

$31.71M

+375.0%

Inventory

$19.90M

+3505.3%

Long Term Debt

$244.53M

+385.4%

Short Term Debt

$7.61M

+2.9%

Return on Assets

-20.12%

N/A

Return on Invested Capital

-20.92%

N/A

Free Cash Flow

-$5.02M

+89.6%

Operating Cash Flow

-$5.07M

+89.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCULOcular Therapeutix, Inc.
$10.77-1.01%
VERAVera Therapeutics, Inc.
$36.82+4.37%
CLDXCelldex Therapeutics, Inc.
$40.57-1.58%
VRDNViridian Therapeutics, Inc.
$24.26+0.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$209.66-0.02%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$116.60+0.01%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$48.09-0.01%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$18.65+0.00%

Questions About NUVB

What is the current price of Nuvation Bio?

Nuvation Bio is trading at $6.96 per share.

What is the 52-week range for Nuvation Bio?

Over the past 52 weeks, Nuvation Bio has traded between $2.87 and $9.75.

How much debt does Nuvation Bio have?

As of the most recent reporting period, Nuvation Bio reported total debt of $416.26M.

How much cash does Nuvation Bio have on hand?

Nuvation Bio reported $258.60M in cash and cash equivalents in its most recent financial results.

What is Nuvation Bio’s dividend yield?

Nuvation Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services